Dr. Gal Strauss Medical Oncologist Specializing in Adult Sarcoma and Bone Tumors
Sheba Medical Center
Dana-Farber Cancer Institute
Harvard Medical School
Tel Aviv University
01 What I treat
-
Soft Tissue Sarcoma
-
Bone Sarcoma
- Osteosarcoma
- Chondrosarcoma
-
Ewing Sarcoma
-
GIST
Gastrointestinal Stromal Tumors
-
Angiosarcoma
-
Leiomyosarcoma
-
Liposarcoma
-
Rhabdomyosarcoma
-
Retroperitoneal Sarcoma
-
Uterine Sarcoma
-
Desmoid
-
Mesothelioma
02 A second opinion
A second opinion is part of the process
in sarcoma care
Consultations take place at the clinic in Ramat Gan or remotely by video — for patients anywhere in Israel, and for patients abroad. For a remote consultation the records are sent and reviewed in full beforehand.
A Who it is for
- A new diagnosis of sarcoma
- Before surgery, while its extent is still open
- Disease progressing on current treatment
- A rare subtype, or an unresolved pathology report
- Assessing eligibility for a clinical trial
- Wanting an existing plan confirmed
B What to bring
- The full pathology report
- Imaging on disc, not only the written report
- Discharge letters and clinic summaries
- Molecular or genetic testing results
- A list of treatments given so far and their dates
- The questions you most want answered
03 Background and training
Board-certified medical oncologist, Director of the Sarcoma Clinic at the Jusidman Oncology Hospital, Sheba Medical Center.
-
2026 — present
Director, Sarcoma Clinic, Sheba Medical Center
-
2024 — 2026
Research Fellow, Dana-Farber
A two-year fellowship in bone and soft tissue sarcoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
-
2023 — 2024
Attending Physician, Sarcoma Unit
In the sarcoma unit and the early phase clinical trials unit at Sheba, alongside leading the high-risk cancer screening clinic.
-
2023
Board certification, Medical Oncology
Israeli Medical Association. Residency at Sheba Medical Center, including service as Chief Resident.
-
2017
MD, Tel Aviv University
Internship at Tel Aviv Sourasky Medical Center (Ichilov).
04 Publications
-
2026
The effect of metformin exposure on colorectal cancer incidence according to tumor sidednessPeerless Y, Strauss G, Margalit O, et al. · Cancer Epidemiol · PMID 41456465
-
2025
Gastrointestinal stromal tumorsStrauss G, George S. · Curr Oncol Rep · PMID 39985704
-
2025
Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome familiesHalpern N, Kventsel I, Strauss G, et al. · Cancer · PMID 40543052
-
2024
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer — outcome and novel predictive markersStemmer A, Margalit O, Strauss G, et al. · Eur J Cancer · PMID 38157568
-
2023
Early systemic anti-neoplastic treatment post SARS-CoV-2 infection in patients with breast cancerHalpern N, Boursi B, Strauss G, et al. · Oncol Ther · PMID 37864026
-
2023
Tumor differentiation as a prognostic marker in clinically staged T1bN0 esophageal adenocarcinomaMargalit O, Shacham-Shmueli E, Strauss G, et al. · Cancer Invest · PMID 37665657
-
2022
Oxaliplatin immune-mediated thrombocytopenia: is there a role for premedication or desensitization?Strauss G, Markovits N, Margalit O, et al. · Br J Clin Pharmacol · PMID 34237795
-
2022
Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinomaMargalit O, Yu S, Strauss G, et al. · J Cancer Res Clin Oncol · PMID 35066662
-
2018
Apparent diffusion coefficient levels and neurodevelopmental outcome in fetuses with brain MR imaging white matter hyperintense signalKatorza E, Strauss G, Cohen R, et al. · AJNR Am J Neuroradiol · PMID 30190257
Contact
Request a consultation
Please send a short email describing the case: the diagnosis, if known, and the main question you would like answered. Every inquiry is read personally.
clinic@galstrauss.comThe clinic
24 Yeshayahu Street
Ramat Gan, Israel
Remote consultation
By video, for patients anywhere
in Israel and abroad